Researchers have posted good results showing favorable tolerability, few infusion site reactions (ISRs), and no serious drug-related adverse events (AEs) of the phase 2b trial of the investigational ultra–long-acting broadly neutralizing…
Researchers have posted good results showing favorable tolerability, few infusion site reactions (ISRs), and no serious drug-related adverse events (AEs) of the phase 2b trial of the investigational ultra–long-acting broadly neutralizing…